Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Int J Pediatr Otorhinolaryngol ; 77(10): 1765-70, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24011938

ABSTRACT

OBJECTIVE: We sought to evaluate the clinical role of pepsin for laryngopharyngeal reflux (LPR) in children with otitis media with effusion (OME). METHODS: Pepsin/pepsinogen and fibrinogen were analyzed in fifty effusion and blood samples of children with OME using enzyme linked immunosorbent assay (ELISA). Ambulatory 24-h dual-probe pH monitoring was additionally performed in 31 children divided into two groups according to response of medical treatment. RESULTS: The effusion levels of pepsin/pepsinogen ranged from 8.5 to 1512 µg/dl and were up to 4-540 times higher than the concentrations found in plasma samples. The effusion levels of fibrinogen ranged from 0.05 to 4.1g/dl. Some effusion samples showed fibrinogen concentrations did not exceed 10 times higher than the concentrations found in plasma samples and others showed lower concentrations. The pH of effusion samples was 7.13 to 8.72. Dual-probe pH monitoring showed that 22/31 (71%) of the studied children had significant acid reflux documented by either the esophageal probe or the pharyngeal probe and all of them had LPR. There is a significant positive correlation between the level of pepsin assayed in the effusions and the number of pharyngeal reflux episodes measured by pH monitoring. CONCLUSIONS: Analysis of pepsin/pepsinogen in effusion samples of children with OME, using ELISA, can be considered as a reliable biochemical marker for assessment of laryngopharyngeal reflux.


Subject(s)
Laryngopharyngeal Reflux/enzymology , Otitis Media with Effusion/enzymology , Pepsin A/metabolism , Pepsinogen A/metabolism , Adolescent , Biomarkers/blood , Biopsy, Needle , Chi-Square Distribution , Child , Cohort Studies , Enzyme-Linked Immunosorbent Assay , Esophageal pH Monitoring , Female , Fibrinogen/analysis , Fibrinogen/metabolism , Follow-Up Studies , Humans , Immunohistochemistry , Laryngopharyngeal Reflux/complications , Laryngopharyngeal Reflux/pathology , Male , Otitis Media with Effusion/complications , Otitis Media with Effusion/pathology , Pepsin A/analysis , Pepsinogen A/analysis , Prospective Studies , Reproducibility of Results , Risk Assessment , Statistics, Nonparametric
2.
Asian Pac J Cancer Prev ; 14(7): 4295-9, 2013.
Article in English | MEDLINE | ID: mdl-23991992

ABSTRACT

BACKGROUND: Pretreatment serum p53 and epidermal growth factor receptor (EGFR) were assessed using enzyme-linked immunosorbent assay (ELISA) in patients with acute leukemia to analysis their roles in characterization of different subtypes of the disease. MATERIALS AND METHODS: Serum samples from thirty two patients with acute myeloid leukemia (AML) and fourteen patients with acute lymphoid leukemia (ALL) were analysed, along with 24 from healthy individuals used as a control group. RESULTS: The results demonstrated a significant increase of serum p53 and EGFR in patients with AML (p<0.0001) compared to the control group. Also, the results showed a significant increase of both markers in patients with ALL (p<0.05, p<0.0001 respectively). Sensitivities and specificities for these variables were 52% and 100% for p53, and 73.9%, 95.8% for EGFR. Serum p53 and EGFR could successfully differentiate between M4 and other AML subtypes, while these variables failed to discriminate among ALL subtypes. A positive significant correlation was noted between p53 and EGFR. Negative significant correlations were observed between these variables and both of hemoglobin (Hg) content and RBC count. CONCLUSIONS: Mutant p53 and EGFR are helpful serological markers for diagnosis of patients with AML or ALL and can aid in characterization of disease. Moreover, these markers may reflect carcinogenesis mechanisms.


Subject(s)
Biomarkers, Tumor/blood , ErbB Receptors/blood , Leukemia, Myeloid, Acute/blood , Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood , Tumor Suppressor Protein p53/blood , Adolescent , Adult , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Female , Follow-Up Studies , Humans , Leukemia, Myeloid, Acute/diagnosis , Male , Middle Aged , Neoplasm Staging , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Prognosis , ROC Curve , Young Adult
3.
Egypt J Immunol ; 12(1): 95-102, 2005.
Article in English | MEDLINE | ID: mdl-16734144

ABSTRACT

It has been reported that Nigella sativa oil possesses anti-inflammatory and bronchodilator activities. Besides, non - toxic and wide margin of safety for therapeutic doses compared with Dexamethasone. This work aims to study the effect of Nigella sativa and Dexamethason on different immune and inflammatory parameters in a mouse model of allergic asthma. Mice sensitized intraperitoneally and challenged intratracheally with conalbumin were treated with Nigella sativa 24 hours after the first intratracheal challenge. Dexamethasone treated and naïve mice served as controls. The effect of Nigella sativa and Dexamethasone treatment on peripheral blood eosinophil count, IgG1 and IgG2a, cytokine profiles and lung inflammation were evaluated. Nigella sativa was significantly reduced peripheral blood eosinophil count, IgG1 and IgG2a levels, cytokine profiles and inflammatory cells in lung tissue. These effects were equivalent to the effects of Dexamethasone except unchanged IFN-y level. Nigella sativa exhibits anti-airway inflammation and immunoregulatory effect which may be useful for treatment of allergic asthma.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Asthma/drug therapy , Cytokines/metabolism , Dexamethasone/pharmacology , Eosinophils , Immunoglobulin G/blood , Nigella sativa , Animals , Asthma/blood , Asthma/immunology , Disease Models, Animal , Leukocyte Count , Male , Mice , Mice, Inbred Strains , Pneumonia/drug therapy , Seeds
4.
Cancer Detect Prev ; 27(2): 127-31, 2003.
Article in English | MEDLINE | ID: mdl-12670524

ABSTRACT

Overexpression of p53 has been found in many types of human malignancy. The present study aimed to detect preoperative serum p53 among 158 patients with different gastrointestinal cancers using ELISA technique based on mouse anti-p53 DO-7 monoclonal antibody and anti-p53 rabbit polyclonal antibody. A single band of 53kDa was detected in nuclear protein tissue extracts of selected cancer patients and in 96% of the corresponding sera using Western blot assay. The ELISA technique revealed that the serum p53 was detected in 100% of patients with cholangiocarcinoma, 76% of pancreatic carcinoma, 75% of hepatocellular carcinoma, 70% of colon cancer, 60% of esophagus carcinoma, and 35% of gastric carcinoma. The serum p53 concentrations of the positive patients were highly elevated (P<0.001) compared with healthy individuals. These results suggest that immunodetection of serum p53 could be valuable for post-operative monitoring during follow up in preoperatively positive patients with gastrointestinal cancers.


Subject(s)
Biomarkers, Tumor/blood , Gastrointestinal Neoplasms/blood , Tumor Suppressor Protein p53/blood , Adult , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Female , Follow-Up Studies , Gastrointestinal Neoplasms/pathology , Gastrointestinal Neoplasms/surgery , Humans , Immunoblotting , Male , Middle Aged , Preoperative Care
SELECTION OF CITATIONS
SEARCH DETAIL
...